Evaluation of the Efficacy, Safety, and Clinical Outcomes of Ginsenosides as Adjuvant Therapy in Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review

被引:2
作者
Zhang, Renjie [1 ]
Liao, Yiling [2 ]
Gao, Yuan [1 ]
Tian, Hengyu [1 ]
Wu, Shenfeng [1 ]
Zeng, Qingteng [1 ]
He, Qinghua [1 ]
Zhang, Ruikun [1 ]
Wei, Chunshan [3 ]
Liu, Jialin [1 ]
机构
[1] Guangzhou Univ Chinese Med, Shenzhen Tradit Chinese Med Hosp, Clin Med Coll 4, Dept Surg 1, 1 Fuhua Rd, Shenzhen 518033, Guangdong, Peoples R China
[2] Guangzhou Univ Chinese Med, Clin Med Coll 4, Shenzhen, Guangdong, Peoples R China
[3] Guangzhou Univ Chinese Med, Shenzhen Tradit Chinese Med Hosp, Clin Med Coll 4, Dept Hepatol, Shenzhen, Guangdong, Peoples R China
关键词
ginsenosides; hepatocellular carcinoma; objective response rate; disease control rate; adverse reactions; clinical efficacy; RG3; CHEMOEMBOLIZATION; PROLIFERATION; SORAFENIB; DIAGNOSIS; CELLS; TACE;
D O I
10.1177/15347354241293790
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ginsenosides (GS), including total GS, Rh2, Rg3 and compound K (CK), have been utilized as adjuvants in transarterial chemoembolization (TACE), surgery, and chemotherapy for hepatocellular carcinoma (HCC) therapy. However, the safety and efficacy of such combination treatments have been contradictory across different studies. This study aims to systematically evaluate the efficacy and safety of GS as adjuvant therapy for HCC. Methods: A literature search of PubMed, CNKI, Wanfang Data, Cochrane Library, Embase, and Web of Science was conducted up to May 2024 for clinical randomized controlled trials (RCTs) on GS-based adjuvant treatments for HCC. Two researchers independently screened the literature, extracted relevant data, and assessed study quality. Meta-analysis was conducted using RevMan 5.4. Results: Nineteen articles involving 1448 patients were included. Meta-analysis showed that GS as an adjuvant therapy for HCC improved disease control rate (risk ratio (RR) = 1.42, 95% CI [1.26, 1.60]), objective response rate (RR = 1.20, 95% CI [1.09, 1.32]), life quality (RR = 1.49, 95% CI [1.23, 1.79]), 1-year overall survival rate (RR = 1.27, 95% CI [1.06, 1.52]), 2-year overall survival rate (RR = 1.43, 95% CI [1.06, 1.95]), ehanced Child-Pugh in A level (RR = 1.59, 95% CI [1.08, 2.34]), Child-Pugh in B level (RR = 1.28, 95% CI [1.08, 1.52]); increased CD3+ (MD = 8.81, 95% CI [3.91, 13.71]), NKC (MD = 8.00, 95% CI [6.76, 9.24]) and CD4+ (MD = 9.38, 95% CI [8.04, 10.72]), and reduced incidence of adverse reactions including nausea and vomiting (RR = 0.66, 95% CI [0.57, 0.77]), anorexia (RR = 0.33, 95% CI [0.21, 0.50]), leukopenia (RR = 0.55, 95% CI [0.46, 0.67]) and myelosuppression (RR = 0.54, 95% CI [0.40, 0.74]); decreased Child-Pugh in C level (RR = 0.43, 95% CI [0.27, 0.68]) and CD4+/CD8+ ratio (MD = 0.50, 95% CI [0.47, 0.57]). Conclusions: In summary, GS combined with Western medical approaches (TACE, surgery, chemotherapy) for the treatment of HCC can improve clinical efficacy, increase overall survival rates, enhance patient life quality, and reduce the occurrence of adverse reactions. However, due to the generally low quality of the included studies, more large-sample, multi-center, high-quality, RCTs are warranted to further consolidate these findings.
引用
收藏
页数:16
相关论文
共 50 条
[1]   Efficacy and safety of neoadjuvant systemic therapy in resectable hepatocellular carcinoma: a Systematic Review and meta-analysis [J].
Wu, Dongdong ;
Liu, Ning ;
Dong, Hao ;
Zhou, Kan ;
Du, Lei ;
Li, Ying ;
Chao, Yanjun ;
Ma, Fuping .
FRONTIERS IN ONCOLOGY, 2025, 15
[2]   Comparison of efficacy and safety of adjuvant therapies versus sorafenib in hepatocellular carcinoma: a systematic review and network meta-analysis [J].
Quan, Wenjun ;
Zulkifli, Hanifah Fazlin ;
Saari, Norhafizah ;
Shueb, Rafidah Hanim ;
Mustaffa, Nazri .
FRONTIERS IN PHARMACOLOGY, 2025, 16
[3]   Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis [J].
Gupta, Nandini ;
Verma, Neelkant ;
Patel, Bhoomika .
JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (04) :1485-1497
[4]   Comparative efficacy and safety of systemic therapy for advanced hepatocellular carcinoma: a systematic review and network meta-analysis [J].
Wu, Di ;
Jia, Binyang ;
Jia, Muyuan ;
Zhao, Haitao ;
Zhao, Hong ;
Zhou, Jinxue .
FRONTIERS IN ONCOLOGY, 2023, 13
[5]   Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis [J].
Xian, F. ;
Song, X. -W. ;
Bie, J. ;
Zhao, C. -X. ;
Zhang, G. -J. ;
Xu, G. -H. .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2024, 28 (02) :687-701
[6]   Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis [J].
Chen, Jiali ;
He, Kun ;
Han, Yunwei ;
Guo, Lu ;
Su, Ke ;
Wu, Zhenying .
ANNALS OF HEPATOLOGY, 2022, 27 (04)
[7]   A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection [J].
Huang, Shenglan ;
Li, Dan ;
Zhuang, LingLing ;
Sun, Liying ;
Wu, Jianbing .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
[8]   A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection [J].
Shenglan Huang ;
Dan Li ;
LingLing Zhuang ;
Liying Sun ;
Jianbing Wu .
World Journal of Surgical Oncology, 19
[9]   Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis [J].
Zhu, Gui-Qi ;
Shi, Ke-Qing ;
Yu, Hua-Jian ;
He, Sun-Yue ;
Braddock, Martin ;
Zhou, Meng-Tao ;
Chen, Yong-Ping ;
Zheng, Ming-Hua .
ONCOTARGET, 2015, 6 (20) :18151-18161
[10]   Efficacy and safety of pembrolizumab in the treatment of advanced hepatocellular carcinoma: a systematic review and meta-analysis [J].
Tang, Mingyang ;
Liu, Tao ;
Zhang, Yukun ;
Ding, Jun .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 81 (06) :815-830